Skip to main content

Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.

Publication ,  Journal Article
Chew, NWS; Mehta, A; Goh, RSJ; Zhang, A; Chen, Y; Chong, B; Chew, HSJ; Shabbir, A; Brown, A; Dimitriadis, GK; Huang, DQ; Foo, R; le Roux, CW ...
Published in: Circulation
January 7, 2025

There is a new awareness of the widespread nature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its connection to cardiovascular disease (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, and the wider multidisciplinary team to address the need for earlier identification of those with MASLD who are at increased risk for CVD. The overlap in the pathophysiologic processes and parallel prevalence of CVD, metabolic syndrome, and MASLD highlight the multisystem consequences of poor cardiovascular-liver-metabolic health. Metabolic dysfunction and associated insulin resistance, together with the predilection for ectopic fat deposition in the liver and surrounding tissues, are associated with elevated risk of endothelial dysfunction, systemic inflammatory response, and ectopic fat deposition in the epicardium. This complex pathophysiology can accelerate atherogenic dyslipidemia, atherogenesis, diastolic dysfunction, valvular calcification, and cardiac arrhythmias. Despite the mounting evidence of mechanistic pathways underpinning MASLD and CVD, current recommendations have not clearly focused upon MASLD as a risk factor or target for intervention in CVD. We have brought together a diverse range of international experts committed to promoting cardiovascular-liver-metabolic health and related outcomes across the globe. The overarching goal of this document is to offer a construct for clinicians in the cardiovascular field with regards to (1) diagnosis and screening of MASLD through the use of noninvasive serum and imaging tests; (2) screening for CVD in all individuals with MASLD regardless of established atherosclerotic risk factors; and (3) the approach to management of MASLD with respect to prevention of CVD through lifestyle, as well as pharmacologic and surgical strategies. To achieve this, the modified Delphi method was applied and a series of evidence-based quality standard recommendations have been identified.

Duke Scholars

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

January 7, 2025

Volume

151

Issue

1

Start / End Page

98 / 119

Location

United States

Related Subject Headings

  • Risk Factors
  • Metabolic Syndrome
  • Mass Screening
  • Humans
  • Fatty Liver
  • Delphi Technique
  • Cardiovascular System & Hematology
  • Cardiovascular Diseases
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chew, N. W. S., Mehta, A., Goh, R. S. J., Zhang, A., Chen, Y., Chong, B., … Sperling, L. S. (2025). Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach. Circulation, 151(1), 98–119. https://doi.org/10.1161/CIRCULATIONAHA.124.070535
Chew, Nicholas W. S., Anurag Mehta, Rachel Sze Jen Goh, Audrey Zhang, Yiming Chen, Bryan Chong, Han Shi Jocelyn Chew, et al. “Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.Circulation 151, no. 1 (January 7, 2025): 98–119. https://doi.org/10.1161/CIRCULATIONAHA.124.070535.
Chew NWS, Mehta A, Goh RSJ, Zhang A, Chen Y, Chong B, Chew HSJ, Shabbir A, Brown A, Dimitriadis GK, Huang DQ, Foo R, le Roux CW, Figtree GA, Fudim M, Pandey A, Mamas MA, Hausenloy DJ, Richards AM, Nicholls SJ, Chan MY, Muthiah MD, Sanyal A, Sperling LS. Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach. Circulation. 2025 Jan 7;151(1):98–119.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

January 7, 2025

Volume

151

Issue

1

Start / End Page

98 / 119

Location

United States

Related Subject Headings

  • Risk Factors
  • Metabolic Syndrome
  • Mass Screening
  • Humans
  • Fatty Liver
  • Delphi Technique
  • Cardiovascular System & Hematology
  • Cardiovascular Diseases
  • 4207 Sports science and exercise
  • 3202 Clinical sciences